AbbVie and Genmab announced that Epkinly did not prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The negative top‑line outcome applies to patients who had received at least one prior therapy, and the companies said they will analyze the data to guide next steps. The result represents a setback for the program and may affect regulatory and commercial plans. AbbVie and Genmab said they will scrutinize subgroups and secondary endpoints and communicate further updates to investors and regulators.